NSCLC患者EGFR-TKI靶向治疗的临床效果及预后分析  

Prognosis of NSCLC patients with EGFR- TKI targeted therapy

作　　者：刘尧[1] 闫晓红[1] 杨乔[1] 侯杰[1] 周海平[1] 王宝锋[2] 耿熠[1] 

机构地区：[1]陕西省宝鸡市中心医院肿瘤内科,陕西宝鸡721008 [2]陕西省宝鸡市中心医院呼吸内科,陕西宝鸡721008

出　　处：《临床和实验医学杂志》2015年第21期1771-1774,共4页Journal of Clinical and Experimental Medicine

摘　　要：目的评估表皮生长因子受体-酪氨酸酶抑制剂(EGFR-TKI)靶向治疗非小细胞肺癌(NSCLC)的临床效果及对患者预后的影响。方法对3年内收治的60例采用EGFR-TKI治疗的NSCLC患者的近期临床疗效进行观察,远期预后进行随访观察,并检测分析治疗前后本组患者的免疫指标、卡氏评分(KPS)及不良反应的发生情况,对EGFR-TKI靶向治疗NSCLC进行效果评价。结果 60例患者,经过6个月的治疗,达到完全缓解者1例(1.67%),部分缓解者19例(31.67%),疾病稳定者25例(41.67%),疾病进展者15例(25.00%),治疗的缓解率为33.33%(20/60),治疗的总有效率为75.00%(45/60)。治疗后患者的KPS评分较治疗前显著提高(t=10.773,P=0.000<0.001)。60例患者在36个月的随访观察中,疾病无进展生存期为11.36±2.48个月,总生存时间为24.88±11.37个月。毒副作用分级主要集中在Ⅰ度、Ⅱ度,表现为轻度或中度的毒副作用。结论 EGFR-TKI靶向治疗NSCLC具有一定的效果,能够改善患者的生活质量,对于延长患者的生存时间具有一定的作用,且毒副作用较轻。Objective To evaluate the clinical efficacy and prognosis of epidermal growth factor receptor tyrosine kinase inhibitor（EGFR- TKI） - targeted therapy for non - small cell lung cancer（ NSCLC）. Methods Sixty NSCLC patients treated with EGFR - TKI - targeted therapy in the last 3 years were studied. The immune parameters,Karnofsky performance score（KPS）and adverse reactions were analyzed before and after the treatment to assess the clinical efficacy of the treatment. The patients were followed - up after treatment to observe the long - term prognosis. Results Of 60 patients,after 6 months of treatment,1 had complete remission（1. 67% ）,19 had partial remission（31. 67% ）,25 had stable disease（41. 67% ）,15 had progressive disease（25% ）. The treatment response rate was 33. 33%（20 / 60）,the total treatment effi-ciency was 75%（45 / 60）. KPS was significantly increased after the treatment than before treatment（ t = 10. 773,P = 0. 000 ﹤ 0. 001）. The 36 months of follow - up showed that progression - free survival was 11. 36 ± 2. 48 months,overall survival was 24. 88 ± 11. 37 months. Toxicity grad-ing was mainly grade 1 and grade 2,the toxicity effect was mild or moderate. Conclusion EGFR - TKI - targeted therapy can improve the quality of life and prolong the survival time of NSCLC patients,and the adverse reactions of the treatment is mild.

关 键 词：非小细胞肺癌 表皮生长因子受体 - 酪氨酸酶抑制剂 靶向治疗 

分 类 号：R734.2[医药卫生—肿瘤]